Streetbeat News

Analyst Ratings

CHDN

JMP Securities analyst Jordan Bender reiterates a Market Outperform rating on Churchill Downs (NASDAQ:CHDN) and maintains a $150 price target.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 3:04 pm

BPMC

JMP Securities analyst Reni Benjamin has reiterated a 'Market Outperform' rating on Blueprint Medicines (NASDAQ:BPMC), maintaining a price target of $114. This reaffirmation of confidence in BPMC's stock performance suggests a positive outlook on the company's future.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 3:02 pm

CTRA

Analyst ratings for Coterra Energy (NYSE:CTRA) show a mix of bullish to bearish sentiments, with recent actions including both upgrades and downgrades. The average 12-month price target is $32.53, up from $32.08. Coterra faces challenges in revenue, net margin, ROE, and ROA, but has a low debt-to-equity ratio. The company operates in the Permian Basin, Marcellus Shale, and Anadarko Basin.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 3:01 pm

VC

Analyst ratings for Visteon (NASDAQ:VC) show mixed sentiments, with recent adjustments in ratings and price targets by key analysts. The average 12-month price target is now $141.43, down 6.16% from the previous average. Visteon's financial performance reveals a negative revenue trend with a -6.95% growth, but strong profitability indicators like a net margin of 36.97%, ROE of 41.54%, and ROA of 14.4%. The company's debt management is also highlighted positively.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 3:01 pm

CAKE

Five analysts have recently evaluated Cheesecake Factory (NASDAQ:CAKE), showing a mix of opinions. The average 12-month price target is now $36.6, up from $32.50, indicating a 12.62% increase. Analysts' ratings range from 'Outperform' to 'Underweight', with recent actions including maintaining and raising price targets. Cheesecake Factory's financial performance shows challenges in revenue growth, net margin, ROE, ROA, and a high debt-to-equity ratio, suggesting potential short-term investment risks.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 3:01 pm

SEIC

SEI Investments (NASDAQ:SEIC) has received mixed analyst ratings in the last three months, with 3 somewhat bullish and 1 indifferent rating. The average 12-month price target has been raised to $75.5, indicating a positive outlook. SEI Investments, a provider of investment services, has shown solid revenue growth and strong financial performance, despite a market capitalization below industry benchmarks and a net margin lagging behind industry averages.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 3:01 pm

LULU

A comparative study of Lululemon Athletica (NASDAQ:LULU) and its competitors in the Textiles, Apparel & Luxury Goods industry reveals LULU's premium valuation and strong financial performance. With higher P/E, P/B, and P/S ratios, LULU is potentially overvalued compared to peers. However, its superior ROE, EBITDA, gross profit, and revenue growth indicate robust profitability and market share expansion, positioning it strongly within the industry.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 3:01 pm

KKR

KKR & Co Inc (NYSE:KKR) is analyzed against competitors in the Capital Markets industry, highlighting its financial metrics, market position, and growth prospects. KKR's PE and PB ratios suggest potential undervaluation, while its PS ratio indicates a rich valuation based on revenue. The company outperforms industry peers in ROE, EBITDA, gross profit, and revenue growth, demonstrating strong operational performance and growth potential.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 3:00 pm

NBIX

Neurocrine Biosciences (NASDAQ:NBIX) has received mixed analyst ratings over the last three months, with a shift towards more bullish sentiment. The average 12-month price target is $153.78, marking an 8.39% increase from the previous target. Analyst actions include both upgrades and downgrades, reflecting responses to market conditions and company performance. Neurocrine Biosciences, a pharmaceutical company, has shown a solid revenue growth rate of 25.05% as of December 31, 2023, but faces challenges in profitability and efficiency metrics compared to industry averages.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 3:00 pm

HCAT

Health Catalyst (NASDAQ:HCAT) has received mixed analyst ratings over the past three months, with 7 analysts offering views that range from bullish to somewhat bullish, with no indifferent, somewhat bearish, or bearish ratings. The 12-month price targets show an average of $13.14, with a high of $16.00 and a low of $10.00, indicating a slight increase from the previous average target of $13.00. The company's financial performance shows positive revenue growth and a strong net margin, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 3:00 pm